AVGN7

About AAVogen

AAVogen is a private, preclinical-stage biotech focused on creating safer, more effective AAV-based gene therapies for muscle disorders. Its core technology involves muscle-tropic AAV vectors engineered to avoid the toxicities seen in other gene therapies, aiming to durably increase muscle mass and strength. The pipeline features AVGN7 for IBM, heart failure, and sarcopenic obesity, and a combination therapy (AVGN7+AVGND) for DMD. Founded by a family personally affected by muscle wasting diseases, the company operates with a lean, virtual model, leveraging key external partners for research, manufacturing, and regulatory strategy.

About AAVogen

AAVogen is a private, preclinical-stage biotech focused on creating safer, more effective AAV-based gene therapies for muscle disorders. Its core technology involves muscle-tropic AAV vectors engineered to avoid the toxicities seen in other gene therapies, aiming to durably increase muscle mass and strength. The pipeline features AVGN7 for IBM, heart failure, and sarcopenic obesity, and a combination therapy (AVGN7+AVGND) for DMD. Founded by a family personally affected by muscle wasting diseases, the company operates with a lean, virtual model, leveraging key external partners for research, manufacturing, and regulatory strategy.

About AAVogen

AAVogen is a private, preclinical-stage biotech focused on creating safer, more effective AAV-based gene therapies for muscle disorders. Its core technology involves muscle-tropic AAV vectors engineered to avoid the toxicities seen in other gene therapies, aiming to durably increase muscle mass and strength. The pipeline features AVGN7 for IBM, heart failure, and sarcopenic obesity, and a combination therapy (AVGN7+AVGND) for DMD. Founded by a family personally affected by muscle wasting diseases, the company operates with a lean, virtual model, leveraging key external partners for research, manufacturing, and regulatory strategy.

Therapeutic Areas

Other Inclusion Body Myositis (IBM) Drugs